Bifogade filer
Kurs
-0,71%
Likviditet
0,03 MSEK
Prenumeration
Kalender
Tid* | ||
2025-10-30 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-07-10 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-22 | N/A | Årsstämma |
2025-05-03 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-02-13 | 07:30 | Bokslutskommuniké 2024 |
2024-12-06 | - | Extra Bolagsstämma 2025 |
2024-11-05 | - | Kvartalsrapport 2024-Q3 |
2024-07-11 | - | Kvartalsrapport 2024-Q2 |
2024-06-28 | - | Årsstämma |
2024-06-12 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2024-05-31 | - | Kvartalsrapport 2024-Q1 |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-07-13 | - | Kvartalsrapport 2023-Q2 |
2023-07-03 | - | Extra Bolagsstämma 2023 |
2023-06-13 | - | Årsstämma |
2023-05-24 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-05-25 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2022-05-24 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-05-26 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2021-05-25 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-07-18 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
2019-05-22 | - | Årsstämma |
2019-05-03 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2023 fiscal year has been published.
The Annual Report is attached and can also be downloaded from the company’s website, www.qlinea.com.
For more information, please contact:
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463
Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.
This information is information that Q-linea is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-12 08:00 CEST.